What's The BUZZ?

Market News, Products, Services, and Trends

Amneal Receives Approval for Leuprolide Acetate

hjklpp.JPG

Key injectable new product launch brings year-to-date injectables launches to 6 


November 2, 2022

BRIDGEWATER, N.J. – Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (“FDA”) for leuprolide acetate for injection. 

Harsher Singh, SVP for Amneal Biosciences stated, “We are making tremendous progress expanding our injectables business. This latest new product is another key therapeutic for the institutional market and another complex, high value launch by the team.”

Leuprolide acetate injection is indicated in the palliative treatment of advanced prostatic cancer. For full prescribing information, see package insert located here. 

According to IQVIA®, U.S. annual sales for this product for the 12 months ended September 2022 were $81 million.

Amneal Pharmaceuticals

Amneal Pharmaceuticals News & Announcements

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) is an integrated specialty pharmaceutical company powered by a robust U.S. generics business and a growing branded business. Together, our team is working to build one of the most dynamic pharmaceutical companies in our rapidly changing industry.

10-rxinsider-staff

Posted by: RXinsider Staff

RXinsider is a multimedia publishing and technology company offering print publications, digital platforms, events, and content creation services to the B2B pharmacy market.

SUBSCRIBE

Name
Subscription Choices
Checkboxes

Request information from Amneal Receives Approval for Leuprolide Acetate

Name
Address
Subscribe